Milan Slavik
- Oncology top 5%
- Molecular Biology
- Cardiology and Cardiovascular Medicine top 5%
- Pulmonary and Respiratory Medicine
- Dermatology top 5%
- Co-authors
- Stephen K. CarterDaniel D. Von HoffMarcel RozencweigFranco M. MuggiaMaxwell W. LayardTodd H. WassermanSewa S. LeghaMichael Goldsmith
- Topics
- Drug Transport and Resistance Mechanisms (6 papers)Cancer Treatment and Pharmacology (5 papers)Synthesis and Biological Evaluation (4 papers)
- Partner nations
- United StatesSouth AfricaMalaysia
In The Last Decade
Milan Slavik
45 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 104
- Oncology 511
- Molecular Biology 347
- Cardiology and Cardiovascular Medicine 304
- Pulmonary and Respiratory Medicine 163
- Dermatology 155
Countries citing papers authored by Milan Slavik
This map shows the geographic impact of Milan Slavik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milan Slavik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milan Slavik more than expected).
Fields of papers citing papers by Milan Slavik
This network shows the impact of papers produced by Milan Slavik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milan Slavik. The network helps show where Milan Slavik may publish in the future.
Co-authorship network of co-authors of Milan Slavik
This figure shows the co-authorship network connecting the top 25 collaborators of Milan Slavik. A scholar is included among the top collaborators of Milan Slavik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milan Slavik. Milan Slavik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 19 | |
| 2 | 3 | |
| 3 | 10 | |
| 4 | 5 | |
| 5 | 34 | |
| 6 | 100 | |
| 7 | 17 | |
| 8 | 16 | |
| 9 | 1 | |
| 10 | 22 | |
| 11 | Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria. | 18 |
| 12 | 3 | |
| 13 | 26 | |
| 14 | 32 | |
| 15 | 70 | |
| 16 | Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. | 90 |
| 17 | 84 | |
| 18 | 47 | |
| 19 | 6 | |
| 20 | 12 |
About Milan Slavik
Milan Slavik is a scholar working on Pharmacology, Oncology and Reproductive Medicine, having authored 46 papers that have together received 1.3k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (6 papers), Cancer Treatment and Pharmacology (5 papers) and Synthesis and Biological Evaluation (4 papers). The work is most often cited by research in Oncology (511 citations), Dermatology (155 citations) and Cardiology and Cardiovascular Medicine (304 citations). Milan Slavik has collaborated with scholars based in United States, South Africa and Malaysia. Frequent co-authors include Stephen K. Carter, Daniel D. Von Hoff, Marcel Rozencweig, Franco M. Muggia, Maxwell W. Layard, Todd H. Wasserman, Sewa S. Legha, Michael Goldsmith, Christopher M. Riley and Steve Dahlberg. Their work appears in journals such as The Lancet, Cancer and Annals of the New York Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.